Global Immuno-oncology Diagnosis Market

Market Size in USD Billion

CAGR : 17.60%

USD 1.14

2025

USD 4.17

2033

Forecast Period	2025 - 2033
Market Size (Base Year)	USD 1.14 Billion
Market Size (Forecast)	USD 4.17 Billion
CAGR	17.60%
Major Market Players	Data provided in full report

Despite the COVID-19 pandemic spreading at a rapid rage across the globe, the Global Immuno-oncology Diagnosis Market has practised certain strategic moves and profitable processes to sustain on both the global and regional platform. This report covers all the significant details including changing market growth rate, market valuation, market growth drivers, restraints, opportunities, and future scope of the Global Immuno-oncology Diagnosis Market in a very elaborative pattern to help the customers capture all the macroscopic and microscopic market trends. Our report provides all the qualitative and quantitative market details that can help the client enhance its business and strategic trends over the forecast period.

Data provided by Extent Research. Source: https://www.extentresearch.com/immuno-oncology-diagnosis-market

Even though the pandemic has affected majority of the key players in the Global Immuno-oncology Diagnosis Market they have adopted various strategies such as signing agreements, acquisitions, mergers, and joint ventures to grow their business in the market over the forecast period. Some of the key players in the Global Immuno-oncology Diagnosis Market include 10x Genomics, Abbott Laboratories, Abcam, Adaptive Biotechnologies, Aethlon Medical, Agena Bioscience, Angle plc, Apocell, ARUP Laboratories, Beckman Coulter, Becton Dickinson, Bioarray Genetics, BioCartis, Biocept, Biodesix Inc, BioFluidica, BioGenex 40 bioMérieux, Bio-Rad, Bio-Techne, Bristol-Myers Squibb, Cancer Genetics, Caris Molecular Diagnostics, CellMax Life, Charles River Laboratories, Chronix Biomedical, Circulogene, Clearbridge BioMedics, Clinical Genomics, Pfizer, Promega, Protagen Diagnostics, Qiagen, Quanterix, Rarecells SAS, Roche Diagnostics, Siemens, . Our research analysts use various research methodologies to represent the geographical distribution and competitive landscape in the representative formats including pie chart, tabular format, bar diagram, graphs, and others. The theoretical and representative detailing in our report clearly explains the growth aspects and scope of the Global Immuno-oncology Diagnosis Market during the forecast period.

Regionally, the Global Immuno-oncology Diagnosis Market is segmented into by Product type PCR, NGS, Immunoassay, , by Application Research, Diagnostics, . The regional distribution in the report provide better answers to the client queries regarding the product scope, economic status, market growth rate, latest trends, and future of the Global Immuno-oncology Diagnosis Market. Our primary goal is to serve our clients with all the significant information including market growth drivers, opportunities & challenges, restraints, competitive landscape, geographical distribution, and market valuation with a customer-centric concept to increase their understanding over the current market status.

Report Scope and Market Segmentation

ATTRIBUTES	Global Immuno-oncology Diagnosis Market KEY MARKET INSIGHTS
Segments Covered	By Product Type: All Products Type Includes By Application: All Application Type Includes By End User: All End User Type Includes By Distribution Channel: All Distribution Channel Includes
Countries Covered	North America U.S., Canada, Mexico Europe Germany, United Kingdom, France, Italy, Spain, Nordic Countries, Benelux Union, Rest of Europe Asia-Pacific China, India, Japan, New Zealand, South Korea, Australia, Southeast Asia, Rest of Asia Pacific Latin America Brazil, Argentina, Rest of Latin America Middle East & Africa Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa
Key Market Players	Leading Tier 1 Corporations Prominent Regional Manufacturers Emerging Market Disruptors Technology Integrators & Suppliers *Complete vendor layout of 15+ major players provided in the final report.
Market Opportunities	Market Size and Growth: Quantifying the total addressable market (TAM) and projected growth rates to assess financial viability. Customer Segmentation: Identifying target audience behaviors, pain points, and specific unfulfilled demands. Competitive Landscape: Analyzing existing competitors' strengths, weaknesses, and market share to pinpoint gaps and opportunities. Industry Trends: Mapping technological, regulatory, and economic shifts that create favorable conditions for market entry. Risk Assessment: Evaluating barriers to entry and operational challenges alongside strategic roadmaps for mitigation.
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by our expert team also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand.

Meet the Team

Julie

Author

Julie Jayne is a distinguished multidisciplinary strategist and the Head of Research at Extent Research, where she leverages over a decade of comprehensive experience in the global market intelligence industry. Backed by a robust academic foundation that includes a B.Sc. and an MBA, she perfectly...

Priya M

Reviewed By

With over 14 years of dedicated professional expertise in business-to-business (B2B) intelligence, Priya M stands as a distinguished leader in corporate strategy, revenue growth, and advanced data analysis. Her dynamic career is defined by a relentless focus on mitigating business risks and empowering corporate executives...

Learn more about Priya M

BASIC ATTRIBUTES \| KEY MARKET INSIGHTS
Report Title	Global Immuno-oncology Diagnosis Market
Base Year	2025
Forecast Period	2025 - 2033
Market Size (Base)	USD 1.14 Billion
Projected Size	USD 4.17 Billion
CAGR	17.60%

                            1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Immuno-oncology Diagnosis Market Size Growth Rate by Type, 2017 VS 2021 VS 2035
        1.2.2 PCR
        1.2.3 NGS
        1.2.4 Immunoassay
    1.3 Market by Application
        1.3.1 Global Immuno-oncology Diagnosis Market Size Growth Rate by Application, 2017 VS 2021 VS 2035
        1.3.2 Research
        1.3.3 Diagnostics
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Immuno-oncology Diagnosis Market Perspective (2017-2035)
    2.2 Immuno-oncology Diagnosis Growth Trends by Region
        2.2.1 Immuno-oncology Diagnosis Market Size by Region: 2017 VS 2021 VS 2035
        2.2.2 Immuno-oncology Diagnosis Historic Market Size by Region (2017-2022)
        2.2.3 Immuno-oncology Diagnosis Forecasted Market Size by Region (2023-2035)
    2.3 Immuno-oncology Diagnosis Market Dynamics
        2.3.1 Immuno-oncology Diagnosis Industry Trends
        2.3.2 Immuno-oncology Diagnosis Market Drivers
        2.3.3 Immuno-oncology Diagnosis Market Challenges
        2.3.4 Immuno-oncology Diagnosis Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Immuno-oncology Diagnosis Players by Revenue
        3.1.1 Global Top Immuno-oncology Diagnosis Players by Revenue (2017-2022)
        3.1.2 Global Immuno-oncology Diagnosis Revenue Market Share by Players (2017-2022)
    3.2 Global Immuno-oncology Diagnosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Immuno-oncology Diagnosis Revenue
    3.4 Global Immuno-oncology Diagnosis Market Concentration Ratio
        3.4.1 Global Immuno-oncology Diagnosis Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Immuno-oncology Diagnosis Revenue in 2021
    3.5 Immuno-oncology Diagnosis Key Players Head office and Area Served
    3.6 Key Players Immuno-oncology Diagnosis Product Solution and Service
    3.7 Date of Enter into Immuno-oncology Diagnosis Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Immuno-oncology Diagnosis Breakdown Data by Type
    4.1 Global Immuno-oncology Diagnosis Historic Market Size by Type (2017-2022)
    4.2 Global Immuno-oncology Diagnosis Forecasted Market Size by Type (2023-2035)
5 Immuno-oncology Diagnosis Breakdown Data by Application
    5.1 Global Immuno-oncology Diagnosis Historic Market Size by Application (2017-2022)
    5.2 Global Immuno-oncology Diagnosis Forecasted Market Size by Application (2023-2035)
6 North America
    6.1 North America Immuno-oncology Diagnosis Market Size (2017-2035)
    6.2 North America Immuno-oncology Diagnosis Market Size by Type
        6.2.1 North America Immuno-oncology Diagnosis Market Size by Type (2017-2022)
        6.2.2 North America Immuno-oncology Diagnosis Market Size by Type (2023-2035)
        6.2.3 North America Immuno-oncology Diagnosis Market Share by Type (2017-2035)
    6.3 North America Immuno-oncology Diagnosis Market Size by Application
        6.3.1 North America Immuno-oncology Diagnosis Market Size by Application (2017-2022)
        6.3.2 North America Immuno-oncology Diagnosis Market Size by Application (2023-2035)
        6.3.3 North America Immuno-oncology Diagnosis Market Share by Application (2017-2035)
    6.4 North America Immuno-oncology Diagnosis Market Size by Country
        6.4.1 North America Immuno-oncology Diagnosis Market Size by Country (2017-2022)
        6.4.2 North America Immuno-oncology Diagnosis Market Size by Country (2023-2035)
        6.4.3 United States
        6.4.4 Canada
7 Europe
    7.1 Europe Immuno-oncology Diagnosis Market Size (2017-2035)
    7.2 Europe Immuno-oncology Diagnosis Market Size by Type
        7.2.1 Europe Immuno-oncology Diagnosis Market Size by Type (2017-2022)
        7.2.2 Europe Immuno-oncology Diagnosis Market Size by Type (2023-2035)
        7.2.3 Europe Immuno-oncology Diagnosis Market Share by Type (2017-2035)
    7.3 Europe Immuno-oncology Diagnosis Market Size by Application
        7.3.1 Europe Immuno-oncology Diagnosis Market Size by Application (2017-2022)
        7.3.2 Europe Immuno-oncology Diagnosis Market Size by Application (2023-2035)
        7.3.3 Europe Immuno-oncology Diagnosis Market Share by Application (2017-2035)
    7.4 Europe Immuno-oncology Diagnosis Market Size by Country
        7.4.1 Europe Immuno-oncology Diagnosis Market Size by Country (2017-2022)
        7.4.2 Europe Immuno-oncology Diagnosis Market Size by Country (2023-2035)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Immuno-oncology Diagnosis Market Size (2017-2035)
    8.2 Asia-Pacific Immuno-oncology Diagnosis Market Size by Type
        8.2.1 Asia-Pacific Immuno-oncology Diagnosis Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Immuno-oncology Diagnosis Market Size by Type (2023-2035)
        8.2.3 Asia-Pacific Immuno-oncology Diagnosis Market Share by Type (2017-2035)
    8.3 Asia-Pacific Immuno-oncology Diagnosis Market Size by Application
        8.3.1 Asia-Pacific Immuno-oncology Diagnosis Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Immuno-oncology Diagnosis Market Size by Application (2023-2035)
        8.3.3 Asia-Pacific Immuno-oncology Diagnosis Market Share by Application (2017-2035)
    8.4 Asia-Pacific Immuno-oncology Diagnosis Market Size by Region
        8.4.1 Asia-Pacific Immuno-oncology Diagnosis Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Immuno-oncology Diagnosis Market Size by Region (2023-2035)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Immuno-oncology Diagnosis Market Size (2017-2035)
    9.2 Latin America Immuno-oncology Diagnosis Market Size by Type
        9.2.1 Latin America Immuno-oncology Diagnosis Market Size by Type (2017-2022)
        9.2.2 Latin America Immuno-oncology Diagnosis Market Size by Type (2023-2035)
        9.2.3 Latin America Immuno-oncology Diagnosis Market Share by Type (2017-2035)
    9.3 Latin America Immuno-oncology Diagnosis Market Size by Application
        9.3.1 Latin America Immuno-oncology Diagnosis Market Size by Application (2017-2022)
        9.3.2 Latin America Immuno-oncology Diagnosis Market Size by Application (2023-2035)
        9.3.3 Latin America Immuno-oncology Diagnosis Market Share by Application (2017-2035)
    9.4 Latin America Immuno-oncology Diagnosis Market Size by Country
        9.4.1 Latin America Immuno-oncology Diagnosis Market Size by Country (2017-2022)
        9.4.2 Latin America Immuno-oncology Diagnosis Market Size by Country (2023-2035)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Immuno-oncology Diagnosis Market Size (2017-2035)
    10.2 Middle East & Africa Immuno-oncology Diagnosis Market Size by Type
        10.2.1 Middle East & Africa Immuno-oncology Diagnosis Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Immuno-oncology Diagnosis Market Size by Type (2023-2035)
        10.2.3 Middle East & Africa Immuno-oncology Diagnosis Market Share by Type (2017-2035)
    10.3 Middle East & Africa Immuno-oncology Diagnosis Market Size by Application
        10.3.1 Middle East & Africa Immuno-oncology Diagnosis Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Immuno-oncology Diagnosis Market Size by Application (2023-2035)
        10.3.3 Middle East & Africa Immuno-oncology Diagnosis Market Share by Application (2017-2035)
    10.4 Middle East & Africa Immuno-oncology Diagnosis Market Size by Country
        10.4.1 Middle East & Africa Immuno-oncology Diagnosis Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Immuno-oncology Diagnosis Market Size by Country (2023-2035)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 10x Genomics
        11.1.1 10x Genomics Company Details
        11.1.2 10x Genomics Business Overview
        11.1.3 10x Genomics Immuno-oncology Diagnosis Introduction
        11.1.4 10x Genomics Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.1.5 10x Genomics Recent Developments
    11.2 Abbott Laboratories
        11.2.1 Abbott Laboratories Company Details
        11.2.2 Abbott Laboratories Business Overview
        11.2.3 Abbott Laboratories Immuno-oncology Diagnosis Introduction
        11.2.4 Abbott Laboratories Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.2.5 Abbott Laboratories Recent Developments
    11.3 Abcam
        11.3.1 Abcam Company Details
        11.3.2 Abcam Business Overview
        11.3.3 Abcam Immuno-oncology Diagnosis Introduction
        11.3.4 Abcam Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.3.5 Abcam Recent Developments
    11.4 Adaptive Biotechnologies
        11.4.1 Adaptive Biotechnologies Company Details
        11.4.2 Adaptive Biotechnologies Business Overview
        11.4.3 Adaptive Biotechnologies Immuno-oncology Diagnosis Introduction
        11.4.4 Adaptive Biotechnologies Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.4.5 Adaptive Biotechnologies Recent Developments
    11.5 Aethlon Medical
        11.5.1 Aethlon Medical Company Details
        11.5.2 Aethlon Medical Business Overview
        11.5.3 Aethlon Medical Immuno-oncology Diagnosis Introduction
        11.5.4 Aethlon Medical Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.5.5 Aethlon Medical Recent Developments
    11.6 Agena Bioscience
        11.6.1 Agena Bioscience Company Details
        11.6.2 Agena Bioscience Business Overview
        11.6.3 Agena Bioscience Immuno-oncology Diagnosis Introduction
        11.6.4 Agena Bioscience Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.6.5 Agena Bioscience Recent Developments
    11.7 Angle plc
        11.7.1 Angle plc Company Details
        11.7.2 Angle plc Business Overview
        11.7.3 Angle plc Immuno-oncology Diagnosis Introduction
        11.7.4 Angle plc Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.7.5 Angle plc Recent Developments
    11.8 Apocell
        11.8.1 Apocell Company Details
        11.8.2 Apocell Business Overview
        11.8.3 Apocell Immuno-oncology Diagnosis Introduction
        11.8.4 Apocell Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.8.5 Apocell Recent Developments
    11.9 ARUP Laboratories
        11.9.1 ARUP Laboratories Company Details
        11.9.2 ARUP Laboratories Business Overview
        11.9.3 ARUP Laboratories Immuno-oncology Diagnosis Introduction
        11.9.4 ARUP Laboratories Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.9.5 ARUP Laboratories Recent Developments
    11.10 Beckman Coulter
        11.10.1 Beckman Coulter Company Details
        11.10.2 Beckman Coulter Business Overview
        11.10.3 Beckman Coulter Immuno-oncology Diagnosis Introduction
        11.10.4 Beckman Coulter Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.10.5 Beckman Coulter Recent Developments
    11.11 Becton Dickinson
        11.11.1 Becton Dickinson Company Details
        11.11.2 Becton Dickinson Business Overview
        11.11.3 Becton Dickinson Immuno-oncology Diagnosis Introduction
        11.11.4 Becton Dickinson Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.11.5 Becton Dickinson Recent Developments
    11.12 Bioarray Genetics
        11.12.1 Bioarray Genetics Company Details
        11.12.2 Bioarray Genetics Business Overview
        11.12.3 Bioarray Genetics Immuno-oncology Diagnosis Introduction
        11.12.4 Bioarray Genetics Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.12.5 Bioarray Genetics Recent Developments
    11.13 BioCartis
        11.13.1 BioCartis Company Details
        11.13.2 BioCartis Business Overview
        11.13.3 BioCartis Immuno-oncology Diagnosis Introduction
        11.13.4 BioCartis Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.13.5 BioCartis Recent Developments
    11.14 Biocept
        11.14.1 Biocept Company Details
        11.14.2 Biocept Business Overview
        11.14.3 Biocept Immuno-oncology Diagnosis Introduction
        11.14.4 Biocept Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.14.5 Biocept Recent Developments
    11.15 Biodesix Inc
        11.15.1 Biodesix Inc Company Details
        11.15.2 Biodesix Inc Business Overview
        11.15.3 Biodesix Inc Immuno-oncology Diagnosis Introduction
        11.15.4 Biodesix Inc Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.15.5 Biodesix Inc Recent Developments
    11.16 BioFluidica
        11.16.1 BioFluidica Company Details
        11.16.2 BioFluidica Business Overview
        11.16.3 BioFluidica Immuno-oncology Diagnosis Introduction
        11.16.4 BioFluidica Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.16.5 BioFluidica Recent Developments
    11.17 BioGenex 40 bioMérieux
        11.17.1 BioGenex 40 bioMérieux Company Details
        11.17.2 BioGenex 40 bioMérieux Business Overview
        11.17.3 BioGenex 40 bioMérieux Immuno-oncology Diagnosis Introduction
        11.17.4 BioGenex 40 bioMérieux Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.17.5 BioGenex 40 bioMérieux Recent Developments
    11.18 Bio-Rad
        11.18.1 Bio-Rad Company Details
        11.18.2 Bio-Rad Business Overview
        11.18.3 Bio-Rad Immuno-oncology Diagnosis Introduction
        11.18.4 Bio-Rad Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.18.5 Bio-Rad Recent Developments
    11.19 Bio-Techne
        11.19.1 Bio-Techne Company Details
        11.19.2 Bio-Techne Business Overview
        11.19.3 Bio-Techne Immuno-oncology Diagnosis Introduction
        11.19.4 Bio-Techne Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.19.5 Bio-Techne Recent Developments
    11.20 Bristol-Myers Squibb
        11.20.1 Bristol-Myers Squibb Company Details
        11.20.2 Bristol-Myers Squibb Business Overview
        11.20.3 Bristol-Myers Squibb Immuno-oncology Diagnosis Introduction
        11.20.4 Bristol-Myers Squibb Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.20.5 Bristol-Myers Squibb Recent Developments
    11.21 Cancer Genetics
        11.21.1 Cancer Genetics Company Details
        11.21.2 Cancer Genetics Business Overview
        11.21.3 Cancer Genetics Immuno-oncology Diagnosis Introduction
        11.21.4 Cancer Genetics Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.21.5 Cancer Genetics Recent Developments
    11.22 Caris Molecular Diagnostics
        11.22.1 Caris Molecular Diagnostics Company Details
        11.22.2 Caris Molecular Diagnostics Business Overview
        11.22.3 Caris Molecular Diagnostics Immuno-oncology Diagnosis Introduction
        11.22.4 Caris Molecular Diagnostics Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.22.5 Caris Molecular Diagnostics Recent Developments
    11.23 CellMax Life
        11.23.1 CellMax Life Company Details
        11.23.2 CellMax Life Business Overview
        11.23.3 CellMax Life Immuno-oncology Diagnosis Introduction
        11.23.4 CellMax Life Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.23.5 CellMax Life Recent Developments
    11.24 Charles River Laboratories
        11.24.1 Charles River Laboratories Company Details
        11.24.2 Charles River Laboratories Business Overview
        11.24.3 Charles River Laboratories Immuno-oncology Diagnosis Introduction
        11.24.4 Charles River Laboratories Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.24.5 Charles River Laboratories Recent Developments
    11.25 Chronix Biomedical
        11.25.1 Chronix Biomedical Company Details
        11.25.2 Chronix Biomedical Business Overview
        11.25.3 Chronix Biomedical Immuno-oncology Diagnosis Introduction
        11.25.4 Chronix Biomedical Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.25.5 Chronix Biomedical Recent Developments
    11.26 Circulogene
        11.26.1 Circulogene Company Details
        11.26.2 Circulogene Business Overview
        11.26.3 Circulogene Immuno-oncology Diagnosis Introduction
        11.26.4 Circulogene Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.26.5 Circulogene Recent Developments
    11.27 Clearbridge BioMedics
        11.27.1 Clearbridge BioMedics Company Details
        11.27.2 Clearbridge BioMedics Business Overview
        11.27.3 Clearbridge BioMedics Immuno-oncology Diagnosis Introduction
        11.27.4 Clearbridge BioMedics Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.27.5 Clearbridge BioMedics Recent Developments
    11.28 Clinical Genomics
        11.28.1 Clinical Genomics Company Details
        11.28.2 Clinical Genomics Business Overview
        11.28.3 Clinical Genomics Immuno-oncology Diagnosis Introduction
        11.28.4 Clinical Genomics Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.28.5 Clinical Genomics Recent Developments
    11.29 Pfizer
        11.29.1 Pfizer Company Details
        11.29.2 Pfizer Business Overview
        11.29.3 Pfizer Immuno-oncology Diagnosis Introduction
        11.29.4 Pfizer Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.29.5 Pfizer Recent Developments
    11.30 Promega
        11.30.1 Promega Company Details
        11.30.2 Promega Business Overview
        11.30.3 Promega Immuno-oncology Diagnosis Introduction
        11.30.4 Promega Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.30.5 Promega Recent Developments
    11.31 Protagen Diagnostics
        11.31.1 Protagen Diagnostics Company Details
        11.31.2 Protagen Diagnostics Business Overview
        11.31.3 Protagen Diagnostics Immuno-oncology Diagnosis Introduction
        11.31.4 Protagen Diagnostics Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.31.5 Protagen Diagnostics Recent Developments
    11.32 Qiagen
        11.32.1 Qiagen Company Details
        11.32.2 Qiagen Business Overview
        11.32.3 Qiagen Immuno-oncology Diagnosis Introduction
        11.32.4 Qiagen Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.32.5 Qiagen Recent Developments
    11.33 Quanterix
        11.33.1 Quanterix Company Details
        11.33.2 Quanterix Business Overview
        11.33.3 Quanterix Immuno-oncology Diagnosis Introduction
        11.33.4 Quanterix Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.33.5 Quanterix Recent Developments
    11.34 Rarecells SAS
        11.34.1 Rarecells SAS Company Details
        11.34.2 Rarecells SAS Business Overview
        11.34.3 Rarecells SAS Immuno-oncology Diagnosis Introduction
        11.34.4 Rarecells SAS Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.34.5 Rarecells SAS Recent Developments
    11.35 Roche Diagnostics
        11.35.1 Roche Diagnostics Company Details
        11.35.2 Roche Diagnostics Business Overview
        11.35.3 Roche Diagnostics Immuno-oncology Diagnosis Introduction
        11.35.4 Roche Diagnostics Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.35.5 Roche Diagnostics Recent Developments
    11.36 Siemens
        11.36.1 Siemens Company Details
        11.36.2 Siemens Business Overview
        11.36.3 Siemens Immuno-oncology Diagnosis Introduction
        11.36.4 Siemens Revenue in Immuno-oncology Diagnosis Business (2017-2022)
        11.36.5 Siemens Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer                        

Research Methodology

Data collection and base year analysis are done using proprietary data collection modules with large sample sizes. The process includes obtaining market information through extensive secondary sources, paid databases, and verifying data via primary (industry expert) validation.

Our market models include Vendor Positioning Grids, Market Timeline Analysis, Company Market Share Analysis, and Top-Down/Bottom-Up forecasting models. To know more about the research methodology, drop an inquiry to speak to our industry experts.

Speak to Analyst

Global Immuno-oncology Diagnosis Market